secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANAPTYSBIO, INC (ANAB)
CIK:        0001370053
Form:       8-K
Filed at:   2023-04-06T23:59:59+00:00
Accession:  0001370053-23-000023
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

AnaptysBio director Laura Hamill resigns; Rita Jain appointed to board and compensation committee
--------------------------------------------------------------------------------

- Laura J. Hamill resigned as Class II director effective April 1, 2023; no disagreement with company.
- Rita Jain, M.D. appointed as Class II director and Compensation Committee member effective April 3, 2023.
- Jain receives pro-rata annual retainer: option for 8,015 shares at April 3 closing price, 3,234 RSUs vesting at 2024 annual meeting.
- Additional grants: option for 10,600 shares and 3,900 RSUs, each vesting over three years.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1370053/000137005323000023/0001370053-23-000023-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1370053/000137005323000023/anab-20230401.htm
  HTML page:      https://secwatch.observer/filing/0001370053-23-000023

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer